Used as an add-on treatment for Parkinson’s disease, particularly during mid to late stages when motor fluctuations become problematic. It helps prolong the effect of levodopa by inhibiting dopamine reuptake and blocking MAO-B, thus increasing dopamine levels in the brain. This results in improved motor control and reduced "off" periods when symptoms return between doses of medication. Additionally, safinamide exhibits glutamate release modulation, which may contribute to neuroprotective effects and symptom stabilization. It is taken orally and offers a favorable side effect profile compared to other Parkinson’s medications, making it suitable for patients seeking both symptomatic relief and potential disease progression delay.